The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Safety and Biodistribution Study of [I-124]-CPD-1028 Injection in Solid Tumours
Official Title: A Phase 1a, Multi-centre, Open-label, Non-randomized Study to Assess the Safety, Biodistribution and Tumour Uptake of [I-124]-CPD-1028 Injection
Study ID: NCT02134340
Brief Summary: The purpose of the study is to evaluate the safety and biodistribution of \[I-124\]-CPD-1028 Injection in cancer patients with solid tumours.
Detailed Description: Up to 18 adult participants will be enrolled in this Phase 1a study to evaluate the safety and biodistribution of \[I-124\]-CPD-1028 Injection in patients with Insulin-like Growth Factor-1R (IGF-1R) upregulated solid tumours. All eligible subjects who have given written informed consent and qualify based on the study's inclusion/exclusion criteria will be enrolled in the study. Each enrolled subject will take part in six visits consisting of a screening visit, an Investigational Product administration visit, 3 assessment visits involving 2-3 Positron Emission Tomography/Computed Tomography (PET/CT) scans, and a follow-up safety telephone call. At Visit 2, subjects will start a course of treatment to protect the thyroid from radioactivity and may receive a pre-targeting dose of an additional investigational agent, CPD-1061.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
Juravinski Cancer Centre, Hamilton, Ontario, Canada
Sunnybrook Health Science Centre - Odette Cancer Centre, Toronto, Ontario, Canada
University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Name: Eric Burak, PhD
Affiliation: Centre for Probe Development and Commercialization
Role: STUDY_DIRECTOR